“Angioplasty” or “percutaneous coronary intervention” means the mechanical reopening of an occluded vessel in the heart or corona using a balloon-tipped catheter.

“Applicant hospital” means a general hospital that has entered into a collaboration agreement with a cardiac surgery center licensed in New Jersey.

“Application” means all information required by the commissioner of an applicant hospital to determine compliance with P.L.2021, c.18 (C. 26:2H-7.22 et al.).

“C-PORT-E study” means the Atlantic Cardiovascular Patient Outcomes Research Team Elective Angioplasty Study clinical trial.

“Collaboration agreement” means an agreement between a licensed cardiac surgery center and a general hospital that includes:

(1) written protocols for enrolled patients who require transfer to, and receipt at, a cardiac surgery center’s operating room within one hour of the determination of the need for such transfer, including the emergency transfer of patients who require an intra-aortic balloon pump;

(2) regular consultation between the two hospitals on individual cases, including use of technology to share case information in a rapid manner; and

(3) evidence of adequate cardiac surgery on-call backup.

“Commissioner” means the Commissioner of Health.

“Department” means the Department of Health.

“Elective angioplasty” means an angioplasty or percutaneous coronary intervention performed on a non-emergent basis.

“Full service adult diagnostic cardiac catheterization facility” means an acute care general hospital that provides invasive cardiac diagnostic services to adult patients without cardiac surgery backup, is equipped with laboratories, and performs at least 250 cardiac catheterizations each year.

“Primary angioplasty” means an angioplasty or percutaneous coronary intervention performed on an acute or emergent basis.

L.2021, c.18, s.1.